Comparative study for the association of mitochondrial haplogroup F+ and metabolic syndrome between longevity and control population in Guangxi Zhuang Autonomous Region, China - 06/12/24

Doi : 10.1007/s12603-017-0915-2

C. Hu ^1,^{*
These authors contributed equally to this work.}, X. He ^1,^{*
These authors contributed equally to this work.}, X. Li ^2,^{*
These authors contributed equally to this work.}, L. Sun ^2,^{*
These authors contributed equally to this work.}, C. Zheng ^3,^{*
These authors contributed equally to this work.}, Q. Liang ^1,^{*
These authors contributed equally to this work.}, Z. Lv ^2,^{*
These authors contributed equally to this work.}, Z. Huang ^4,^{*
These authors contributed equally to this work.}, K. Qi ^5,^{*
These authors contributed equally to this work.}, H. Yuan ^2,^{*
These authors contributed equally to this work.}, X. Zhu ^2,^{*
These authors contributed equally to this work.}, Y. Yang ^2,^{*
These authors contributed equally to this work.}, Q. Zhou ^2,^{*
These authors contributed equally to this work.}, Ze Yang ^2,^{*
These authors contributed equally to this work.}
¹ Department of Neurology, Jiangbin Hospital, Nanning, Guangxi, P.R. China
² The MOH key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, No.1 DaHua Road, Dong Dan, 100730, Beijing, P.R. China
³ Department of Cardiothoracic Surgery, Guangxi Maternal and Child Health Hospital, Nanning, Guangxi, P.R. China
⁴ Yongfu committee of the Chinese people’s political consultative conference, Yongfu, Guangxi, P.R. China
⁵ Lab of Genetics and Metabolism, Beijing Obstetrics and Gynecology Hospital, Beijing, P.R. China

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

Our previous study suggested that mitochondrial haplogroup F (mtDNA F) was a longevity-associated biomarker, but the effect of mitochondrial haplogroup F on longevity individuals with metabolic syndrome (MetS) was not clear. Thus we explored the association between mtDNA F and MetS among longevity and control population in Guangxi Zhuang Autonomous Region, China.

Method

A total of 793 individuals consisting of 307 long-lived participants and 486 local healthy controls were involved in this study. Genotypes of mtDNA F were amplified by polymerase chain reaction and Sanger sequenced. MetS was defined according to the revised National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATPIII ) criteria.

Results

The prevalence of MetS in longevity group (28.0%) was higher than that (18.5%) in control group (P=0.002). Through the case-control stratify analysis, the prevalence of MetS in mtDNA F+ longevity individuals (29.8%) was 4.6 fold higher than that (5.3%) in local control group (P<0.001). However, after further longevity-only analysis, no association between MetS and mtDNA F+ in longevity group was observed (P=0.167). Following same analysis of two variables in control group, we found that the prevalence of MetS in mtDNA F- (95.8%) was higher than that in mtDNA F+ (5.3%); conversely, the prevalence of non-metabolic syndrome (NMetS) in mtDNA F+ (94.7%) was markedly higher than that in mtDNA F- (4.2%) (P<0.001).

Conclusion

We demonstrated that mtDNA F+, as a molecuar biomarker, might not only confer beneficial effect to resistance against MetS but also function as a positive factor for long-life span among the population in Guangxi Zhuang Autonomous Region, China.

Le texte complet de cet article est disponible en PDF.

Key words : Metabolic syndrome, mtDNA haplogroup F, longevity, Guangxi Zhuang autonomous region